Tanvex BioPharma, a Taiwan-based biopharmaceutical company, announced this week the submission of its Biologics License Application (BLA) to the FDA for TX-01, a proposed filgrastim biosimilar referencing Neupogen.
Tanvex BioPharma, a Taiwan-based biopharmaceutical company, announced this week the submission of its Biologics License Application (BLA) to the FDA for TX-01, a proposed filgrastim biosimilar referencing Neupogen.
Click here to read more about biosimilar filgrastim.
Tanvex announced that it would be seeking the same indications for TX-01 as the reference product is currently approved for: the treatment of chemotherapy-induced neutropenia. According to data from IQVIA, filgrastim sales for Neupogen, Zarxio, and Granix combined were estimated to be $700 million in the United States last year, and Tanvex hopes to capture a share of that market.
“The submission of the BLA for TX-01 represents an exciting milestone for Tanvex. Such a remarkable action takes Tanvex one step closer to launching its very first biosimilar product in the [United States] market,” said Allen Chao, MD, CEO of Tanvex Biopharma.
Tanvex is also in the midst of developing 3 other biosimilars: TX-05, a proposed trastuzumab biosimilar, referencing Herceptin, is currently beginning phase 3 trials for the treatment of HER2-positive breast cancer; TX-16, a potential bevacizumab biosimilar, referencing Avastin, is nearing the conclusion of phase 1 trials and is being investigated for the treatment of metastatic colorectal cancer; and TX-17, a proposed adalimumab biosimilar, referencing Humira, is still in the preclinical phase and is being developed to treat patients with rheumatoid arthritis.
To date, there are 2 filgrastim biosimilars available for use in the United States: Zarxio and Nivestym, the latter of which just recently came to market at a 30.3% discount to the reference product. Though there is a third filgrastim on the market, tbo-filgrastim, sold as Granix, it is not technically a biosimilar due to the fact that it earned FDA approval prior to the creation of the biosimilar approval pathway.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Revolutionizing Biopharmaceuticals: The EU's Biosimilar Success and Remaining Challenges
October 16th 2024The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, lowering costs, and increasing adoption; however, there remains a need for more education, real-world evidence, and efforts to address challenges to enhance patient access and affordability.
IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics
October 14th 2024During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.